Ran BPC-157 solo at 250mcg 2x/day subcu bc if it’s blended, you can’t tell what’s doing what. first cycle (4 wks), nothing obvious. second cycle i did subq near the shoulder, same dose, 4 wks. felt like maybe some mobility gain, but honestly could’ve been the concurrent deload. here’s the thing: if you’re in a blend w/ BPC + TB-500 + some MK, and sides show up or you feel something, which compound? if you get swelling, nausea, nothing at all - you’re flying blind. individual costs more, more pinning, but you actually isolate the variable. only thing i’d add: if you’re just asking “did it work”, blend is probably fine. but if you want to know which peptide moved the needle, especially with side effects, you need individual. that’s why the question matters.
ran the same protocol structure for the same reason. BPC solo first cycle, four weeks, logged ROM before and during. The “could’ve been the concurrent deload” caveat is the part nobody wants to write down, but it’s the entire ballgame. I got 11 degrees flexion over six weeks with concurrent PT and I still cannot cleanly attribute that to the peptide vs the loading protocol vs just being further out from surgery. Isolating the compound is step one, isolating the rehab variable is step two and almost nobody does both.
edit: forgot to add
solo-first is the right structural call, and your second cycle write-up basically proves it: you ran BPC alone and still couldn’t separate the mobility gain from the deload. that’s the part most people miss. isolating one compound doesn’t isolate the variable if PT, sleep, and loading are all moving underneath. you need a baseline period before the pin starts. ROM degrees, pain score, sleep quality, ideally two weeks of stable measurements pre-dose. otherwise “maybe some mobility gain” is still a vibe, just a more expensive vibe than the blend version. side effect attribution is a stronger argument for solo than efficacy attribution, fwiw. swelling at the injection site has fewer confounders than “did my shoulder get better.”
your 11 degrees tells you something happened, but without a pt-only baseline from that same 6-week window, you don’t know what. isolating the compound works; isolating rehab is the hard part bc you’d need that control. you’re right almost nobody does both, but it’s structural - you can’t rerun the surgery. that’s why
one variable the individual-vs-blend framing doesn’t account for: hormonal background if you’re on HRT. estradiol directly modulates collagen synthesis and tendon mechanics, so if your levels shift between cycle 1 and cycle 2, you’ve introduced a moving variable that has nothing to do with which peptide you’re running. i’ve seen this in my own tracking - working sets stall when estradiol dips, independent of whatever else is in the protocol at the time. individual is still cleaner than blend. but the baseline isn’t static even when you control for compounds, and almost nobody is tracking that axis alongside their peptide cycles.
edit: clarifying
the “can’t rerun the surgery” line is the structural problem and most people skip past it. my own numbers for context: 140 deg flexion / 35 deg ER the morning before surgery, 78 / 18 at week 8 when i started the BPC solo run. picked up 11 deg flexion over the 4-wk cycle, but i was also six weeks deeper into PT by then with the loading getting heavier. so the 11 is real, i just can’t attribute it. ran TB-500 on the second cycle and my pt flagged less scar tissue formation going in, which is exactly the kind of soft observation that’s impossible to anchor without a control period i don’t have. the variable that sits outside the biochemical framing entirely is mechanotransduction. collagen fiber alignment in tendon depends on mechanical loading signals, no peptide addresses that directly afaik. my physio raised it early in rehab and i keep coming back to it when threads get too deep into “which compound did what.” the loading is doing work the peptide can’t do even in theory, and that’s invisible if you’re only tracking compound variables. one thing that helped me at least see the shape of the noise: i started stacking the ROM line against sleep quality in a tracker. the careclinic one has an overlay view where you put two metrics on the same timeline, and the ROM dips lined up with bad sleep nights more than i expected. doesn’t solve attribution but it tells you which confounds are stacking on which weeks. worth doing if you’ve already got the discipline to log a baseline.
eta: one more thing
the deload confound is the actual problem here, not the blend question. four weeks of BPC solo w/ a concurrent deload means you can’t attribute anything to the peptide anyway, which is the same isolation failure you’re critiquing in blends. if you want to know whether proximal subq moved the needle on your shoulder specifically, you need a control period where the only variable is injection site, same training load, same everything else. the “did it work” vs “which compound” framing is useful though, i’ll give you that. most people asking about blends are asking the first question without realizing they need to answer the second to get a clean signal.
Cycle 2 had two things change at once, which is where the isolation argument starts to undercut itself: subq placement shifted to near the shoulder and a deload ran concurrently for the full four weeks. A deload moves systemic inflammation, joint loading, and sleep architecture simultaneously, which is exactly the same class of variable-stacking problem you’re arguing against in blends, just applied to the training side of the protocol instead of the compound side. Individual dosing solves attribution within the vial. It doesn’t cover what else is moving around the protocol, and the “maybe some mobility gain, but honestly could’ve been the concurrent deload” read reflects exactly that gap.
the isolation logic holds, but “concurrent deload” doing the heavy lifting is exactly the kind of confounder that buries these results. run eight weeks of BPC solo, make zero other changes, and you’re still not certain because time heals tissue too. that’s not a knock on the individual approach, it’s just the ceiling you hit with any uncontrolled n=1. where i’d push back slightly: the blend-vs-individual framing assumes your goal is attribution. for a lot of guys it isn’t. if the shoulder just needs to work again and you’re not publishing anything, running them together is fine, you’re accepting the ambiguity in exchange for coverage. the tradeoff isn’t really “blend good, individual bad,” it’s “what question are you actually trying to answer.” but the methodology point stands for side effects specifically. if you’re trying to figure out what caused the water retention or the nausea or the insomnia, you absolutely need to know what’s in the pin. stacking compounds when sides appear is the worst time to be flying blind.
“concurrent deload” doing real work in cycle two is exactly the problem. the isolation logic is right in principle - blend gives you noise, individual gives you something to act on if sides show up. imo but you also changed injection site between cycles, generic subcu in cycle one vs. subq near the shoulder in cycle two, and that’s not a neutral variable for BPC. there’s actual debate in the literature about whether proximal vs. distal injection changes the local effect, so that swap counts as its own variable. add the deload and you’ve got at least three things moving on a supposedly controlled solo run. individual compound is necessary but not sufficient. you need to freeze everything else too, or you’re just paying more for the same muddy signal. expensive muddy data is still muddy data. the “blend is probably fine if you just want did it work” framing falls into the same hole - that question is equally unanswerable if the window isn’t clean. the discipline of isolation matters more than the individual vs. blend decision itself. ymmv but that’s what i’ve found running bpc solo for the shoulder.
Solo compound doesn’t fully close the variable problem either, and the shoulder detail you mentioned is why. BPC at these subq doses stays pretty localized - hypovascular tissue doesn’t distribute it far from the pin site. Cycle 1 you didn’t specify site, cycle 2 you ran near the shoulder. Same compound, same dose, different tissue exposure. If you got a mobility signal in cycle 2 that wasn’t there in cycle 1, you can’t cleanly call that a cycle effect vs. a site effect - those aren’t the same thing. Individual protocol is the right call over a blend, no argument there. But individual + site-held-constant across cycles is the actual clean experiment. Blend vs. individual is step one. Consistent site placement is step two. imo The concurrent deload you flagged is a third confounder and that’s a separate problem entirely. solo just eliminates one variable, not all of them.
Sourcing consistency is a variable that doesn’t show up here, and it complicates “isolate the variable” more than people admit. Two cycles, same vendor, same declared 250mcg, doesn’t mean same purity or same batch. I log sourcing per compound now, not just per supplier, bc I found that customs behavior varies by specific compound from the same source. So your cycle 1 vs cycle 2 comparison already has a batch variable floating in it, independent of the site change. Individual dosing narrows the category. It doesn’t fix the product variable. Worth logging lot numbers if you can get them.
the case for individual is real. if you’re running BPC + TB + MK and get nausea, you have three suspects with no way to narrow it. but “individual compound” doesn’t actually close the loop if the training variable is still loose. your own second cycle is the example: BPC solo, concurrent deload, “maybe some mobility gain.” that’s not isolation, that’s one fewer confounder. crossover design does more work than individual-vs-blend framing alone.
“concurrent deload” is doing a lot of work in this post, honestly. even running bpc solo i’ve got basically the same attribution problem at three weeks - localized swelling, some nerve stuff, sleep going from fragmented 4-5 hours to solid 6-7, and rom shifting at the same time. i can tell something moved. i can’t tell which variable caused which. the confound isn’t only compound-vs-compound, it’s compound-vs-everything-else-that-shifted in the same window. blends make it worse for sure, but solo doesn’t clean it up as much as it sounds - you’d need to freeze training load, sleep, stress, and diet simultaneously to actually isolate the peptide, and nobody realistically does that.
the confound nobody’s really running at is timing within the day. even solo bpc, if you’re dosing twice daily, pre-workout vs post-workout changes what tissue environment the peptide hits. sleep timing too. i went from 4-5 to 6-7 hrs solid over roughly the same window i was running subq near the shoulder, and i genuinely cannot tell if the rom shift was bpc, the sleep, or the deload. point being: isolation by compound is step one, but you’ve also got n+1 other variables shifting underneath it. individual is smarter than a blend for this, but it’s still not clean. that’s my take.